Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food Effect Study of Bersiporocin in Healthy Adults
NCT04767815Phase 1Completed
- Sponsor
- Daewoong Pharmaceutical
- Start
- Mar 2021
- Primary completion
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of bersiporocin in idiopathic pulmonary fibrosis (IPF) (6 arms), sponsored by Daewoong Pharmaceutical. Primary endpoints: Maximum Plasma Concentration (Cmax) of DWN12088 and metabolite at Day 15, Area Under the Curve to the last measurable concentration (AUClast) of DWN12088 and metabolite at Day 15 and 1 more. Started Mar 2021; status: completed.
02
Drugs
bersiporocin
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT04767815.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04767815.